Navigation Links
Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
Date:8/28/2007

SEATTLE, Aug. 28 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTAX: CTIC) today announced that it had received a Deficiency Letter (the "Letter") from Nasdaq indicating that the Company's recently completed registered offering of Series C 3% Convertible Preferred Stock (the "Series C Preferred") and warrants did not comply with voting rights requirements set forth in Nasdaq Marketplace Rule 4351 and IM 4351. The Nasdaq staff verbally notified the Company of such noncompliance on August 9, 2007 and, in response to this verbal notification, the Company took action to cure the deficiency by amending the Articles of Amendment of the Company's Articles of Incorporation, which set forth the rights and preferences of the holders of the Series C Preferred (the "Articles of Amendment"). The amendment to the Articles of Amendment (the "Amendment") adjusted the conversion ratio of the Series C Preferred for purposes of the voting rights provision of the Articles of Amendment, and had the effect of reducing the number of votes that the holders of the Series C Preferred have because it increased the conversion price from $3.90 to $4.53 for purposes of the voting rights provision. The Amendment did not change the conversion price in any other provision of the Articles of Amendment, including but not limited to the provision on conversion of such Series C Preferred into shares of common stock.

The letter confirms that, subject to the public announcement requirements of Nasdaq Marketplace Rule 4803(a), the Company has regained compliance with Nasdaq Marketplace Rule 4351 and IM 4351 and the matter is now closed.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit http://www.cticseattle.com.

'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Canadian firm buys Proventiv Therapeutics, makes ex-Bone Care exec CEO
2. Milwaukee takes another step in electronic patient data exchange
3. Ethics Board site offers welcome contrast to state IT mistakes
4. It takes more than money to reach the top
5. CATI takes tech transfer model national
6. Green economic plan takes cue from Indiana
7. Local software company takes Google to court over a patent
8. American Family CIO takes entrepreneurial approach to innovation
9. TDS takes top spot in region in customer satisfaction rankings
10. Innovative health care takes more than just IT automation
11. Centralization mania takes over
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... Earle Martin , Chief ... that Ellen Teplitzky, an experienced attorney specializing in ... industry, has joined the firm as Director of ... practice. NDA Partners provides legal services, including ... to top law firms and their clients in ...
(Date:10/19/2014)... OCTOBER 20-22, 2014: The 9th ... will take place at the Congress Center ... is now available at http://www.abim.ch . ... organizations from all over the globe will ... latest products and developments on the world ...
(Date:10/19/2014)... Asian Automatic patient billing report defines and segments the ... The Automatic patient billing market in Asia is estimated ... a developing CAGR of 7.2% from 2013 to 2018. ... patient billing market, to get an idea of the ... the segmentation of this market in the same region, ...
(Date:10/19/2014)... The Asian Orthopedic braces and support systems ... analysis and forecast of revenue. The Orthopedic braces and support ... $416.5 million by 2018, at a developing CAGR of 4.4% ... the Asian Orthopedic braces and support systems market, to get ... a glimpse of the segmentation of orthopedic braces and support ...
Breaking Biology Technology:NDA Partners Appoints Ellen Teplitzky, JD as Director of its Legal Services Practice 2The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 2The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 3The Asian Orthopedic braces and support systems market is estimated to grow to around $416.5 million by 2018 - New Report by MicroMarket Monitor 2The Asian Orthopedic braces and support systems market is estimated to grow to around $416.5 million by 2018 - New Report by MicroMarket Monitor 3The Asian Orthopedic braces and support systems market is estimated to grow to around $416.5 million by 2018 - New Report by MicroMarket Monitor 4
... June 14, 2010 Executives from Senexis,Limited (Cambridge,UK) signed an ... with chemistry services to support a patent,filing on a novel chemical series ... Disease. , , , ... Dr. Mark Treherne , CEO of Senexis said that he ...
... ... is focused on centralizing information to meet researchers, needs. , ... (PRWEB) -- STEMCELL Technologies Inc has just launched ... centralizing information to meet researchers, needs., , ,The site has been completely redesigned to provide ...
... ... of Lev Verkh, PhD as Chief Regulatory and Clinical Development Officer. Dr. Verkh will be ... , ... Stemedica Cell Technologies, Inc ., a leader in adult stem cell research and manufacturing, ...
Cached Biology Technology:O2h Continues to Support Senexis to Support Patent Filing Senexis Limited 2STEMCELL Technologies Inc Launches New Website 2Stemedica Announces the Appointment of Dr. Lev Verkh as Chief Regulatory and Clinical Development Officer 2
(Date:10/16/2014)... SHELTON, Conn. , October 16, 2014 ... ("NXT-ID" or the "Company"), a biometric authentication company focused ... present its leading edge technologies including Wocket™, the Smart ... Review® (FiRe) Conferenece. FiRe is a leading global conference ... Hosted by Mark Anderson , founder ...
(Date:10/15/2014)... admitted Johannes Gutenberg University Mainz (JGU) as a ... continues to maintain a significant nationwide standing in ... acceptance of Johannes Gutenberg University Mainz as a ... in the national and international competition for the ... Rhineland-Palatinate can be proud that Mainz University has ...
(Date:10/15/2014)... Rosenstiel Award for Distinguished Work in Biomedical Science by ... of genomic instability and its implications for the immune ... to win the Rosenstiel Award; the first, Rod McKinnon, ... the Charles A. Janeway Professor of Pediatrics and Professor ... at the Howard Hughes Medical Institute at Boston Children,s ...
Breaking Biology News(10 mins):NXT-ID Inc. to Present at 13th Annual FiRe Conference 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 3Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 3Brandeis awards 44th Rosenstiel Award to pioneering geneticist Fred Alt 2
... Scientists have shown they can dramatically enhance radiation's cancer-killing ... that promotes cancer growth. Blocking a protein called HIF-1 ... took for human cancers to begin growing again in ... Cancer Center. , Each therapy alone had limited or ...
... physician and scientist, who has spent the best part of ... and AIDS throughout the world, is calling for global strategies ... pandemic. , Quinn, a professor of infectious diseases at Hopkins ... and Infectious Disease, reports that women have in the last ...
... of the body's molecules controls the trafficking of T cells ... fight infection -- a crucial response that sometimes goes awry, ... The traffic control system -- composed of a fat-like compound ... prevents T cells from launching harmful reactions. But when the ...
Cached Biology News:Duke Experiments Boost Radiation's Cancer-Killing Effects 2Duke Experiments Boost Radiation's Cancer-Killing Effects 3AIDS expert says global strategy needed to combat feminization of HIV/AIDS 2AIDS expert says global strategy needed to combat feminization of HIV/AIDS 3Discovery of T-cell 'traffic control' boosts new drug promise 2Discovery of T-cell 'traffic control' boosts new drug promise 3Discovery of T-cell 'traffic control' boosts new drug promise 4
... The Helios gene gun system, 100-120 V, ... biomaterials into cells. This handheld device employs ... RNA-, and other biomaterial-coated gold microcarriers from ... cartridge directly into target cells. This system ...
... polyclonal antibody raised against a ... Immunogen: ZFHX4 (NP_078997, ... partial recombinant protein with GST ... Number: NM_024721 ...
... raised against a partial recombinant ... K6HF (NP_004684, 141 a.a. ... protein with GST tag. ... NM_004693 Protein ...
... The binding specificity and signaling of ... known to be modified by alternative splicing--which ... GPCR SpliceArrays you can perform a classical ... detect the different alternatively spliced forms of ...
Biology Products: